Biodesix Inc
NASDAQ:BDSX
Intrinsic Value
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. [ Read More ]
The intrinsic value of one BDSX stock under the Base Case scenario is 3.06 USD. Compared to the current market price of 1.26 USD, Biodesix Inc is Undervalued by 59%.
Valuation Backtest
Biodesix Inc
Run backtest to discover the historical profit from buying and selling BDSX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biodesix Inc
Current Assets | 39.7m |
Cash & Short-Term Investments | 26.3m |
Receivables | 7.7m |
Other Current Assets | 5.7m |
Non-Current Assets | 59.4m |
PP&E | 29.6m |
Intangibles | 22.9m |
Other Non-Current Assets | 6.9m |
Current Liabilities | 33.4m |
Accounts Payable | 2.9m |
Accrued Liabilities | 5.1m |
Other Current Liabilities | 25.4m |
Non-Current Liabilities | 61.1m |
Long-Term Debt | 35.2m |
Other Non-Current Liabilities | 25.9m |
Earnings Waterfall
Biodesix Inc
Revenue
|
49.1m
USD
|
Cost of Revenue
|
-13m
USD
|
Gross Profit
|
36.1m
USD
|
Operating Expenses
|
-77.4m
USD
|
Operating Income
|
-41.3m
USD
|
Other Expenses
|
-10.8m
USD
|
Net Income
|
-52.1m
USD
|
Free Cash Flow Analysis
Biodesix Inc
BDSX Profitability Score
Profitability Due Diligence
Biodesix Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Biodesix Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
BDSX Solvency Score
Solvency Due Diligence
Biodesix Inc's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Score
Biodesix Inc's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDSX Price Targets Summary
Biodesix Inc
According to Wall Street analysts, the average 1-year price target for BDSX is 3.57 USD with a low forecast of 3.54 USD and a high forecast of 3.68 USD.
Ownership
BDSX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BDSX Price
Biodesix Inc
Average Annual Return | -26.94% |
Standard Deviation of Annual Returns | 70.65% |
Max Drawdown | -97% |
Market Capitalization | 144.1m USD |
Shares Outstanding | 114 334 000 |
Percentage of Shares Shorted | 0.57% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
Contact
IPO
Employees
Officers
The intrinsic value of one BDSX stock under the Base Case scenario is 3.06 USD.
Compared to the current market price of 1.26 USD, Biodesix Inc is Undervalued by 59%.